Skip to Main Content

Paper Details

CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy.
Cancer Causes Control
7
2019
BC, CYP2D6, P450 enzyme, Tamoxifen, breast cancer, early-stage, estrogen, estrogen-sensitive breast cancers, germline, tamoxifen, women
Author NameAffiliation
Scott T WeissUniversity of Washington
Scott T WeissFred Hutchinson Cancer Research Center
Scott T WeissUniversity of Washington
Scott T WeissFred Hutchinson Cancer Research Center
Christopher S CarlsonFred Hutchinson Cancer Research Center
Christopher S CarlsonFred Hutchinson Cancer Research Center
Kathleen E MaloneUniversity of Washington
Kathleen E MaloneFred Hutchinson Cancer Research Center
  • 1 - 8

Datasets

Release 1.2